ZAP Surgical and Swiss Neuro Radiosurgery Center Announce Imminent Installation of New Gyroscopic Radiosurgery Platform for Treating Brain Tumors

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

ZAP Surgical Systems, Inc. today announced the imminent installation of its advanced ZAP-X® Gyroscopic Radiosurgery® platform at the Swiss Neuro Radiosurgery Center (SNRC), an organization within the Swiss Clinical Neuroscience Institute (SCNSI) in Zurich, Switzerland.

Stereotactic radiosurgery (SRS) is a well-studied and effective treatment for many brain cancers including primary and metastatic brain tumors, as well as select intracranial functional and vascular disorders. Considered an alternative to surgery for these indications, SRS is a non-invasive outpatient procedure that often provides equivalent to superior outcomes, yet no surgical incision, and little to no recovery period.

The ZAP-X system is recognized for using gyroscopic motion to direct radiosurgical beams from a multitude of unique angles which precisely concentrate radiation to the tumor target, resulting in significantly less healthy brain tissue exposure than those of multi-purpose radiation delivery systems. This unique approach supports the clinical objective of protecting healthy brain tissue and neuro-cognitive function.

ZAP-X is also the first and only dedicated radiosurgery system to no longer require Cobalt-60 radioactive sources, thus eliminating the significant costs to license, secure and regularly replace live radioactive isotopes.

“The local core-team consisting of neurosurgeon Christoph Weber, MD, radiation oncologist Cristina Picardi, MD, and myself are looking forward to putting Switzerland’s first ZAP-X into operation,” said Andreas Mack, PHD, founder and chief executive officer of SNRC.

“With an interdisciplinary focus on neuro-radiosurgical treatments, the project is a cooperative effort including the Klinik Hirslanden Institute for Radiotherapy, the Center for Endoscopic and Minimally Invasive Neurosurgery, namely Robert Reisch, MD, and Nikolai Hopf, MD, and the Center for Micro Neurosurgery, namely Ralf Kockro, MD,” added Mack. “Additionally, SNRC is scientifically advised by the clinical team at the University Hospital of Basel, Department of Neurosurgery, namely Luigi Mariani, MD, Raphael Guzman, MD, and Ethan Taub, MD.”

ZAP Surgical is excited to partner with SNRC to bring world-class radiosurgery to Zurich and the surrounding communities,” said Hakan Baraner, ZAP Surgical’s Senior Vice President for Europe, Middle East, and Africa. “We believe SNRC’s ZAP-X program will serve as an example to many other medical centers, both locally and globally.”

SNRC estimates first patient treatments with ZAP-X will commence in the summer of 2021.

 

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles